Egypt Breast Cancer Therapeutics Market Analysis Report 2022 to 2030

Egypt Breast Cancer Therapeutics Market Analysis

$ 3999

Egypt's breast cancer therapeutics market is projected to grow from $51 Mn in 2022 to $149 Mn by 2030, registering a CAGR of 14.4% during the forecast period of 2022-30. Strong immunotherapeutic acceptance and favorable reimbursement policies in Egypt have led to the growth of Egypt's breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. MDI Pharma, Minapharm Pharmaceuticals, and Bristol-Myers Squibb are some leading companies in Egypt's breast cancer therapeutics market.

ID: IN10EGPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Parul Choudhary

Buy Now

Egypt Breast Cancer Therapeutics Market Executive Analysis

Egypt's breast cancer therapeutics market size is at around $51 Mn in 2022 and is projected to reach $149 Mn in 2030, exhibiting a CAGR of 14.4% during the forecast period. Following the budgetary allotments for public services, social protection, and education, the healthcare investment budget is currently the fourth largest in Egypt's overall public budget. The research states that from 2016 through 2021, healthcare services accounted for an average of 5.2% of total government spending, or 1.5% of GDP. An almost 30% increase from the $0.88 Bn that was allocated for 2021–2022, public spending in healthcare is planned at $1.14 Bn for 2022–2023.

Breast cancer accounts for 33% of female cancer cases in Egypt and more than 22,000 new cases are reported every year. Given the expanding population, shifting population pyramid, and adoption of the Westernized lifestyle, this is anticipated to increase rapidly over the coming years. An estimated 30,000 new cases of breast cancer are recorded annually in Egypt, where the prevalence of the disease is rising. Cultural and socioeconomic hurdles, a lack of knowledge, a lack of access to early detection and treatment options, and a high incidence of breast cancer are all thought to play a role in Egypt. Mammography screening programs and breast cancer awareness campaigns are only two examples of recent initiatives to promote early detection and access to care.

egypt breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Strong immunotherapy acceptance and favorable reimbursement policies in Egypt are seen as promising signs for the expansion of Egypt's breast cancer therapeutics market. The expansion of the Egypt breast cancer therapeutics market is anticipated to be fuelled by increasing healthcare spending as well as greater awareness of breast cancer.

Market Restraints

Many Egyptians may find the cost of breast cancer treatment, which includes medications and surgery, to be unaffordable, and some of the more modern and advanced breast cancer therapies may not be widely accessible in Egypt, which would restrain the market's expansion for Egypt breast cancer therapeutics.

Competitive Landscape

Key Players

EVA Pharma (EGY)
Hikma Pharmaceuticals (EGY)
MDI Pharma (EGY)
Minapharm Pharmaceuticals (EGY)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Cancer patients in Egypt are treated in hospitals run by the General Authority for Health Insurance, the Ministry of Health and Population, or university hospitals at public expense, or in the private sector with the patients' own money or with their own insurance. Nongovernmental organizations assist cancer patients in a variety of ways, including financing public hospitals and offering medical services. In order to achieve universal health care, Egypt supported the Universal Health Insurance (UHI) law in 2018. The UHI law seeks to provide coverage for the entire populace by securing revenue through fresh, varied financing methods. Egypt has a tiered system in place for its reimbursement policy for breast cancer care, which is based on the patient's financial level. Patients from lower income brackets are entitled to free care, while those from higher income brackets could need to cover some of the expenses.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.